The phenotypic spectrum of X‐linked, infantile onset ALG13‐related developmental and epileptic encephalopathy
Developmental and epileptic encephalopathy
Male
Drug Resistant Epilepsy
Developmental Disabilities
epileptic spasms
Adrenocorticotropic Hormone / therapeutic use
Epileptic Syndromes / physiopathology
Anticonvulsants / therapeutic use
info:eu-repo/classification/ddc/618
Child
0303 health sciences
Glucocorticoids / therapeutic use
Drug Resistant Epilepsy / therapy
Drug Resistant Epilepsy / genetics
Electroencephalography
Dyskinesias / genetics
Magnetic Resonance Imaging
3. Good health
Developmental Disabilities / genetics
Phenotype
Neurology
Child, Preschool
Full‐length Original Research
Developmental Disabilities / physiopathology
Anticonvulsants
Female
Epileptic spasms
Diet, Ketogenic
Language Development Disorders / physiopathology
Language Development Disorders / genetics
Drug Resistant Epilepsy / physiopathology
Clinical Neurology
Mutation, Missense
610
N-Acetylglucosaminyltransferases
ALG13
03 medical and health sciences
Adrenocorticotropic Hormone
Journal Article
Humans
Language Development Disorders
developmental and epileptic encephalopathy
Social Behavior
Glucocorticoids
N-Acetylglucosaminyltransferases / genetics
Dyskinesias
Infant
West syndrome
Hormones
Spasms, Infantile / physiopathology
Hormones / therapeutic use
Spasms, Infantile / genetics
Epileptic Syndromes / genetics
Dyskinesias / physiopathology
Epileptic Syndromes
Epileptic Syndromes / therapy
DOI:
10.1111/epi.16761
Publication Date:
2021-01-10T18:49:06Z
AUTHORS (27)
ABSTRACT
AbstractObjectiveAsparagine‐linked glycosylation 13 (ALG13) deficiencies have been repeatedly described in the literature with the clinical phenotype of a developmental and epileptic encephalopathy (DEE). Most cases were females carrying the recurrent ALG13 de novo variant, p.(Asn107Ser), with normal transferrin electrophoresis.MethodsWe delineate the phenotypic spectrum of 38 individuals, 37 girls and one boy, 16 of them novel and 22 published, with the most common pathogenic ALG13 variant p.(Asn107Ser) and additionally report the phenotype of three individuals carrying other likely pathogenic ALG13 variants.ResultsThe phenotypic spectrum often comprised pharmacoresistant epilepsy with epileptic spasms, mostly with onset within the first 6 months of life and with spasm persistence in one‐half of the cases. Tonic seizures were the most prevalent additional seizure type. Electroencephalography showed hypsarrhythmia and at a later stage of the disease in one‐third of all cases paroxysms of fast activity with electrodecrement. ALG13‐related DEE was usually associated with severe to profound developmental delay; ambulation was acquired by one‐third of the cases, whereas purposeful hand use was sparse or completely absent. Hand stereotypies and dyskinetic movements including dystonia or choreoathetosis were relatively frequent. Verbal communication skills were absent or poor, and eye contact and pursuit were often impaired.SignificanceX‐linked ALG13‐related DEE usually manifests as West syndrome with severe to profound developmental delay. It is predominantly caused by the recurrent de novo missense variant p.(Asn107Ser). Comprehensive functional studies will be able to prove or disprove an association with congenital disorder of glycosylation.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (35)
CITATIONS (14)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....